Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial

Autor: Pasquale F. Innominato, Annabelle Ballesta, Qi Huang, Christian Focan, Philippe Chollet, Abdoulaye Karaboué, Sylvie Giacchetti, Mohamed Bouchahda, René Adam, Carlo Garufi, Francis A. Lévi

Publikováno v: Cancer Medicine, Vol 9, Iss 12, Pp 4148-4159 (2020)

Abstract The least toxic time (LTT) of irinotecan varied by up to 8 hours according to sex and genetic background in mice. The translational relevance was investigated within a randomized trial dataset, where no LTT stood out significantly in the who

Externí odkaz: https://doaj.org/article/2990600537df42ceb50e3ef287e9b467

Circadian rest‐activity rhythm as an objective biomarker of patient‐reported outcomes in patients with advanced cancer

Autor: Pasquale F. Innominato, Sandra Komarzynski, Oxana G. Palesh, Robert Dallmann, Georg A. Bjarnason, Sylvie Giacchetti, Ayhan Ulusakarya, Mohamed Bouchahda, Mazen Haydar, Annabelle Ballesta, Abdoulaye Karaboué, Nicholas I. Wreglesworth, David Spiegel, Francis A. Lévi

Publikováno v: Cancer Medicine, Vol 7, Iss 9, Pp 4396-4405 (2018)

Abstract Background Psychosocial symptoms often cluster together, are refractory to treatment, and impair health‐related quality of life (HR‐QoL) in cancer patients. The contribution of circadian rhythm alterations to systemic symptoms has been o

Externí odkaz: https://doaj.org/article/e4e3a0683bbc487d80d05d53f77dea47

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial

Autor: Pasquale F, Innominato, Abdoulaye, Karaboué, Christian, Focan, Philippe, Chollet, Sylvie, Giacchetti, Mohamed, Bouchahda, Ayhan, Ulusakarya, Angela, Torsello, René, Adam, Francis A, Lévi, Carlo, Garufi

Publikováno v: International Journal of Cancer

The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage treatment. We aimed at assessing its safety and efficacy profiles with its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fb14ba44d2606412f0a00013c9418c4a
https://pubmed.ncbi.nlm.nih.gov/33270911

Chronomodulated Versus Fixed-Infusion—Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial

Autor: Francis A. Lévi, Rachid Zidani, Jean-Michel Vannetzel, Bruno Perpoint, Christian Focan, Roberto Faggiuolo, Philippe Chollet, Carlo Garufi, Moshe Itzhaki, Luigi Dogliotti, Stefano lacobelli, René Adam, Francis Kunstlinger, Julio Gastiaburu, Henri Bismuth, Claude Jasmin, Jean-Louis Misset

Publikováno v: JNCI: Journal of the National Cancer Institute. 86:1608-1617

BACKGROUND In a previous phase II trial, circadian (chronomodulated) delivery of fluorouracil (5-FU), folinic acid (FA; leucovorin), and oxaliplatin (1-OHP; a new platinum complex with no renal and minor hematologic toxic effects) produced an objecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f79ea7a857879cd2c72a035c950212a
https://doi.org/10.1093/jnci/86.21.1608

Neo-wt- RAS in ctDNA: Is It Worth Using Anti-EGFR Therapies?

Autor: Innominato PF; Pasquale F. Innominato, MD, PhD, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom; Abdoulaye Karaboué, MD, PhD, UPR 'Chronotherapy, Cancer and Transplantation,' Medical School, Paris-Saclay University, Villejuif, France, Medical Oncology Unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil, France; and Francis A. Lévi, MD, PhD, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom, UPR 'Chronotherapy, Cancer and Transplantation,' Medical School, Paris-Saclay University, Villejuif, France, Gastro-intestinal and Medical Oncology Service, Paul Brousse Hospital, Villejuif, France., Karaboué A; Pasquale F. Innominato, MD, PhD, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom; Abdoulaye Karaboué, MD, PhD, UPR 'Chronotherapy, Cancer and Transplantation,' Medical School, Paris-Saclay University, Villejuif, France, Medical Oncology Unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil, France; and Francis A. Lévi, MD, PhD, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom, UPR 'Chronotherapy, Cancer and Transplantation,' Medical School, Paris-Saclay University, Villejuif, France, Gastro-intestinal and Medical Oncology Service, Paul Brousse Hospital, Villejuif, France., Lévi FA; Pasquale F. Innominato, MD, PhD, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom; Abdoulaye Karaboué, MD, PhD, UPR 'Chronotherapy, Cancer and Transplantation,' Medical School, Paris-Saclay University, Villejuif, France, Medical Oncology Unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil, France; and Francis A. Lévi, MD, PhD, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom, UPR 'Chronotherapy, Cancer and Transplantation,' Medical School, Paris-Saclay University, Villejuif, France, Gastro-intestinal and Medical Oncology Service, Paul Brousse Hospital, Villejuif, France.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Nov; Vol. 8, pp. e2400628. Date of Electronic Publication: 2024 Nov 07.